Home / Companies / Lineage Cell Therapeutics, Inc. / 6 Sep 2023
Lineage Cell Therapeutics, Inc.: meeting of 6 Sep 2023
Votes reported on Form N-PX, item by item
156 Form N-PX filers reported votes at the Lineage Cell Therapeutics, Inc. meeting of 6 Sep 2023. Their records fall into 7 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
9 nominees; 79.1% of reported votes for; 43 filers withheld from or voted against at least one nominee.
684 vote records from 45 filers. 2 of the 44 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
198 vote records from 152 filers. 10 of the 143 filers that marked the item either way voted against management. 9 filers reported this item without a management mark.
One filer reported a share count too large to be the holding described. No share split is published for this item. How that is decided
SECTION 14A SAY-ON-PAY VOTESIssuer
Frequency of the say-on-pay vote
one year: 134 filers; for: 5 filers; three years: 2 filers; not applicable: 2 filers; 1-year: 1 filer; : 1 filer.
199 vote records from 152 filers. 2 of the 141 filers that marked the item either way voted against management. 11 filers reported this item without a management mark.
One filer reported a share count too large to be the holding described. No share split is published for this item. How that is decided
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
76 vote records from 45 filers. 0 of the 44 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
76 vote records from 45 filers. 0 of the 44 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
83 vote records from 47 filers. 9 of the 46 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
76 vote records from 45 filers. 5 of the 44 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Pay-vote frequency | 4. Auditor |
|---|---|---|---|---|
| Vanguard | For | For | Split or no vote | For |
| BlackRock and iShares | For | For | Split or no vote | For |
| Fidelity | For | For | Split or no vote | For |
| Dimensional | No report | For | Split or no vote * | No report |
| State Street and SPDR | For | For | Split or no vote | For |
| Invesco | No report | Against * | Split or no vote | No report |
| Equitable | For | For | Split or no vote | For |
| Charles Schwab | For | For | Split or no vote | For |
| Nuveen and TIAA | For | For | Split or no vote | For |
| ProShares and ProFunds | For | For | Split or no vote | For |
| John Hancock and Manulife | For | For | Split or no vote | For |
| Morgan Stanley, Eaton Vance and Calvert | For | Against * | Split or no vote | For |
| J.P. Morgan | No report | For | Split or no vote | No report |
| Goldman Sachs | No report | For | Split or no vote | No report |
| PGIM and Prudential | No report | For | Split or no vote | No report |
| Jackson National funds | For | For | Split or no vote * | For |
| Northern Trust and FlexShares | For | For | Split or no vote | For |
| T. Rowe Price | For | For | Split or no vote | For |
| Lincoln Financial | For | For | Split or no vote | For |
| Voya | For | For | Split or no vote | For |
| Nationwide | For | For | Split or no vote | For |
| Victory Capital | For | For | Split or no vote | For |
| Brighthouse Funds | For | For | Split or no vote | For |
| Guggenheim and Rydex | For | For | Split or no vote | For |
| BNY Mellon | No report | For | Split or no vote | No report |
| Principal | For | For | Split or no vote | For |
| Pacific Life funds | For | For | Split or no vote | For |
| AllianceBernstein | No report | For | Split or no vote | No report |
| DWS | For | For | Split or no vote | For |
| Janus Henderson | No report | For | Split or no vote | No report |
| Neuberger Berman | No report | For | Split or no vote | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Lineage Cell Therapeutics, Inc. meeting?
156 Form N-PX filers reported votes at the meeting of 6 Sep 2023. On say-on-pay, 10 of 143 voted against management (7.0%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Lineage Cell Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Lineage Cell Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Lineage Cell Therapeutics, Inc. with a meeting date within three days of 6 Sep 2023. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.